SituGen

SituGen is a South Korean biotechnology company specializing in the discovery of small molecule inhibitors for protein-protein interactions (PPIs). The company utilizes its proprietary SituGen platform, which enables the screening of drug candidates in a cellular environment that mimics physiological conditions, identifying compounds that might be missed by traditional biochemical assays. Their primary therapeutic focus includes oncology and metabolic disorders, where PPIs play a critical role in disease progression but are often considered 'undruggable.' Founded in 2018 as a spin-off from Chung-Ang University, SituGen is currently advancing several pre-clinical programs targeting high-value interfaces such as KRAS and c-Myc. The company's technology integrates high-throughput screening with advanced molecular biology to accelerate the development of first-in-class therapeutics.